The RPAH Institute of Haematology Research Unit is a leader in both clinical medicine and laboratory research spanning malignant and non-malignant haematology. The clinical trials unit has been very active in multiple diseases over many years, investigating and making available many state-of-the-art agents and protocols for their patients.
The Institute of Haematology is one of the highest recruiters of many Australian and multi-national clinical trials in Haematology. Their clinical trial activity covers a wide portfolio.
Despite the COVID-19 pandemic their trials unit continued to expand in 2020 commencing fourteen new phase I-III trials. The changes to the hospital required by the pandemic proved a challenge but no trials patient was left untreated.
We are delighted to welcome The Institute of Haematology at RPAH to CT:IQ’s Steering Committee and look forward to collaborating on future projects.